Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open‐label, long‐term extension study. AIMS: The primary objective of OCTAVE Open was to assess the safety and tolerability of long‐term tofac...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandborn, William J., Lawendy, Nervin, Danese, Silvio, Su, Chinyu, Loftus, Edward V., Hart, Ailsa, Dotan, Iris, Damião, Adérson O. M. C., Judd, Donna T., Guo, Xiang, Modesto, Irene, Wang, Wenjin, Panés, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Safety and Efficacy of Tofacitinib in Ulcerative Colitis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300081/
https://www.ncbi.nlm.nih.gov/pubmed/34854095
http://dx.doi.org/10.1111/apt.16712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300081/
https://www.ncbi.nlm.nih.gov/pubmed/34854095
http://dx.doi.org/10.1111/apt.16712

Ejemplares similares